Welcome to our dedicated page for Atea Pharmaceuticals SEC filings (Ticker: AVIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Atea is a clinical-stage biopharmaceutical company focused on oral antiviral therapies for serious viral infections, and its filings help investors understand how it reports on clinical progress, financial condition and corporate governance.
Among the key documents are Form 8-K current reports, which Atea uses to announce material events such as quarterly financial results and related business updates. For example, 8-K filings dated August 7, 2025 and November 12, 2025 reference press releases detailing results of operations for the quarters ended June 30 and September 30, respectively, along with other matters described in those releases. These 8-Ks also confirm that Atea’s common stock is listed on The Nasdaq Global Select Market under the symbol AVIR.
Another important filing type is the proxy statement on Schedule 14A, summarized in a June 20, 2025 Form 8-K covering the company’s annual meeting of stockholders. That 8-K reports voting outcomes on the election of Class II directors, ratification of the independent registered public accounting firm and an advisory vote on executive compensation, providing insight into shareholder participation and governance decisions.
Through Stock Titan, users can track Atea’s ongoing Exchange Act reporting, including how it furnishes press releases as exhibits, discloses results of operations under Item 2.02 of Form 8-K, and reports shareholder meeting results under Item 5.07. Real-time updates from EDGAR are paired with AI-powered summaries that explain the structure and key points of filings, helping readers quickly identify items related to clinical-stage spending, cash balances, listing status on The Nasdaq Global Select Market and board or shareholder actions.
For those researching AVIR, this page offers a structured view of Atea’s regulatory history, from financial updates to governance matters, with tools to interpret the implications of each filing.
Atea Pharmaceuticals EVP and Chief Accounting Officer Wayne Foster reported equity compensation and related share activity. On January 31, 2026, 33,333 and 8,000 restricted stock units (RSUs) converted into an equal number of Atea common shares as vesting and performance conditions were met.
Following these conversions (coded M), Foster held 91,461 common shares before tax withholding. A separate transaction (code F) shows 12,132 shares withheld at $4.24 per share to cover taxes, leaving 79,329 common shares held directly.
Foster also received a new stock option grant for 108,000 shares at a $4.24 exercise price. The option vests in forty‑eight equal monthly installments after January 31, 2026, becoming fully vested on January 31, 2030, with 108,000 options beneficially owned directly after the grant.
Atea Pharmaceuticals, Inc. filed a current report to disclose that it issued a press release with its preliminary unaudited cash and investment balance as of December 31, 2025. The details of this estimated balance are contained in the press release furnished as Exhibit 99.1.
The company emphasizes that this financial information is preliminary, based on currently available data, and remains subject to completion of its fourth-quarter and full-year 2025 financial closing and audit procedures. The information has not been audited or reviewed by its independent registered public accounting firm and is furnished, not filed, meaning it is not subject to certain Exchange Act liability provisions or automatically incorporated into other securities filings.
Atea Pharmaceuticals (AVIR) filed its Q3 2025 10-Q, highlighting continued investment in its hepatitis C program and a strong liquidity position. The company reported a net loss of $42.0 million for the quarter and $113.5 million year-to-date, driven primarily by R&D as Phase 3 trials advance. R&D was $38.3 million in Q3, with HCV external costs a key component.
Cash, cash equivalents and marketable securities totaled $329.3 million as of September 30, 2025, and management believes this will fund operations through 2027. The balance sheet shows total assets of $343.0 million and stockholders’ equity of $315.8 million. Atea completed its $25.0 million share repurchase program in 2025, including 3,054,195 shares bought for $11.4 million in Q3. Shares outstanding were 78,126,796 as of November 10, 2025.
The Phase 3 HCV program (C-Beyond in the US/Canada and C-Forward ex-North America) began enrollment in April and June 2025. Atea maintains an at-the-market facility with Jefferies for up to $200.0 million; no shares were sold as of September 30, 2025. The company previously reduced headcount by ~25%, targeting aggregate savings of approximately $15 million through 2027.
Atea Pharmaceuticals, Inc. (AVIR) furnished its quarterly earnings press release for the three months ended September 30, 2025. The company reported this under Item 2.02 of Form 8-K on November 12, 2025. The press release is furnished as Exhibit 99.1 and incorporated by reference.
The Item 2.02 information, including Exhibit 99.1, is expressly stated as not deemed “filed” under Section 18 of the Exchange Act and not incorporated into Securities Act or Exchange Act filings unless specifically referenced. The filing also lists Exhibit 104 for the cover page Inline XBRL tags.
Form 4 filing (24-Jun-2025) reveals that Atea Pharmaceuticals (AVIR) director Franklin M. Berger increased his ownership through equity-based compensation granted on 20-Jun-2025. A total of 29,600 previously issued restricted stock units (RSUs) vested and converted into common shares (Code M) at a $0.00 cost, lifting his direct holdings to 506,497 shares. Concurrently, Berger received 29,600 new RSUs that will vest at the next annual meeting or one-year anniversary, and 41,200 stock options with a $3.25 exercise price expiring 19-Jun-2035, vesting monthly over 12 months. No shares were sold. The transactions signal net insider accumulation while introducing modest potential dilution through the new RSUs and options.